Vascular Smooth Muscle Cell Migration and P70S6K: Key Players in Intimal Hyperplasia Development

Area of Science:

• Cardiovascular Biology
• Translational Medicine
• Pharmacology

Background:

• Vascular smooth muscle cell (VSMC) activation drives intimal hyperplasia (IH) and restenosis post-injury.
• Drug-eluting stents with mTOR blockers (e.g., everolimus [EV]) show limitations in efficacy and specificity.
• Kv1.3 channel blockers (e.g., PAP-1) previously demonstrated potential in preventing IH.

Purpose of the Study:

• To investigate the combined effects of PAP-1 and EV on IH development.
• To explore the underlying molecular mechanisms, including pathway crosstalk in VSMCs.
• To identify potential surrogate markers for IH progression.

Main Methods:

• In vivo studies using a mouse carotid ligation model.
• Ex vivo organ culture of human vessels.
• In vitro studies on primary human VSMCs, assessing cell migration, proliferation, and pathway signaling (mTOR, MEK/ERK, P70S6K).

Main Results:

• Individually, PAP-1 and EV inhibited IH, but their combination unexpectedly exacerbated IH.
• The combination abolished inhibition of VSMC migration and potentiated proliferation.
• A crosstalk between mTOR and MEK/ERK pathways, mediated by P70S6K activation, was identified, correlating with IH development.

Conclusions:

• VSMC migration, not proliferation, is the primary driver of the observed effects of PAP-1 and EV on IH.
• VSMC P70S6K phosphorylation is a reliable surrogate marker for IH progression.
• The complex, non-monotonic responses suggest a NOR gate-like mechanism, offering novel insights for IH prevention strategies.